Genmab — December 2018
-
Nikhil Munshi, MD, discusses the POLLUX and CASTOR studies regarding the use of daratumumab in MM https://www.youtube.com/watch?v=TIS7rogeP20
-
Det er udlandet, der køber op i
Genmab=derfor stigning. -
Det er vist Danske eller Nordea som står for salg og køb i bonusprogrammerne.
-
Spændende om den holder 1020 i dag?
-
-
-
over ASH we heard ´Importantly, this study did demonstrate that despite the significant improvement with daratumumab in the initial PSF1, it did not impact the response of the patient in the next line of therapy. Therefore, the PSF2 was improved in the daratumumab arm."´
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind